Eli Lilly (NEO:LLY)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Eli Lilly Charts. Click Here for more Eli Lilly Charts.](/p.php?pid=staticchart&s=NEO%5ELLY&p=8&t=15)
The Larry King Cardiac Foundation Receives $100,000 Grant from
Lilly to Support 'Save a Heart a Day'
Needy patients also will have access to medication through Lilly patient
assistance program
WASHINGTON, Feb. 10 /PRNewswire-FirstCall/ -- The Larry King Cardiac
Foundation (LKCF) announces a new partnership with Eli Lilly and Company to
help combat heart disease. In support of the Foundation's ambitious goal to
"save a heart a day," Lilly has committed to a $100,000 grant as well as
donation of the vital anti-thrombotic medication, ReoPro(R) (abciximab) through
Lilly's patient assistance program, Lilly Cares.*
This effort greatly enhances the Foundation's efforts to provide life- saving
cardiac care for those who cannot afford it. Many of those individuals might
not be alive today without the help of the foundation or they would be facing
large medical bills.
"I was fortunate enough to have medical insurance cover my heart surgery and
procedures," said Larry King, founder of The Larry King Cardiac Foundation and
internationally renowned host of CNN's "Larry King Live." "Heart disease takes
the lives of 500,000 men and women annually in the United States. This funding
and cardiac medication from Lilly is a big step in helping us save a heart a
day."
The anti-thrombotic, ReoPro(R), is the Foundation's first donation of
medication. During angioplasty procedures to open blockages in arteries that
supply blood to the heart, ReoPro(R) is used to help prevent formation of blood
clots in the heart and help diminish clots that already have formed.
LKCF provides cardiac care and resources through affiliate partners for
individuals who, due to limited means and inadequate insurance, would otherwise
be unable to receive treatment. The Foundation works in conjunction with
hospitals throughout the nation to ensure that such patients receive proper
medical attention.
"Lilly is pleased to be the first company to provide product to the Larry King
Cardiac Foundation. This donation is part of our overall worldwide efforts to
help indigent patients have access to medications that save and improve lives,"
said Dr. Hunter Heath, executive director, U.S. Medical Division, Lilly. "It
is particularly appropriate that we donate the cardiovascular drug ReoPro,
which has helped save lives for 10 years now. Cardiovascular disease is a
leading killer today, and we are dedicated to working to improve the lives of
people who suffer from this devastating disease."
Under the partnership, Lilly will work with medical centers participating in
the LKCF affiliate care program to provide product to eligible patients through
the Lilly Cares prescription assistance program. These hospitals include:
Children's National Medical Center and George Washington University Medical
Center, both in Washington, D.C.; Cedars-Sinai Medical Center and Childrens
Hospital Los Angeles, both in Los Angeles; Weill Cornell Medical Center and New
York Presbyterian Hospital, in New York.
ReoPro was developed by Centocor of Malvern, Pa., USA, and is manufactured by
Centocor, B.V., in Leiden, the Netherlands. Eli Lilly and Company markets and
distributes the product worldwide except in Japan.
For more information regarding The Larry King Cardiac Foundation, please go to
http://www.lkcf.org/ . Contact Linda Roth at . For more information on
Lilly, please contact Janice Chavers at .
*Eligible patients will receive product at no cost through the Lilly Cares
program.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050209/LKCLOGO )
http://www.newscom.com/cgi-bin/prnh/20050209/LKCLOGO
DATASOURCE: The Larry King Cardiac Foundation
CONTACT: Linda Roth of The Larry King Cardiac Foundation,
, +1-703-522-0703, http://www.lkcf.org/